From Lead Compounds to Potential Therapeutics: Drugs to Treat Clostridium Difficile Infections

从先导化合物到潜在治疗药物：治疗艰难梭菌感染的药物

• 批准号: nhmrc : GNT1124032
• 负责人: Prof Dena Lyras
• 金额: $ 52.35万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/lead-compounds-potential-difficile-infections/1347378
• 关键词: Lead; Compounds; Potential; Therapeutics; Drugs

Clostridium difficile infection (CDI) attacks the gut resulting in diarrhoea and inflammation of the colon. It is classified as the number one antibiotic-resistant bacterial threat in the USA where there are 500,000 cases of CDI and 30,000 deaths. CDI is an increasing problem for hospitalized patients in the US, the EU and Australia. Our recent NHMRC funded project established drug leads against CDI and we now require continued studies to develop our drug leads towards marketable therapeutics.

艰难梭菌感染(CDI)攻击肠道，导致腹泻和结肠炎。它被列为美国头号抗药性细菌威胁，美国有500,000例CDI病例和30,000人死亡。在美国、欧盟和澳大利亚，CDI对住院患者来说是一个日益严重的问题。我们最近由NHMRC资助的项目确定了针对CDI的药物线索，我们现在需要继续研究，以将我们的药物线索发展到市场上的治疗药物。